To design and implement a platform for merging administrative data from Local Health Units (drug consumptions, hospital discharge, etc.) with clinical data from Biologic Drugs Registries in order to assess appropriateness, appraise long-term effects in a real-world setting, identify chronic-care model and ensuring cost sustainability. METHODS: CINECA Italian Interuniversity Consortium has developed an online system for data collection and analysis on biological drugs for the treatment of rheumatic, gastroenterological and dermatological diseases. Patient registration, disease evaluation, therapeutic plans (TPs), follow-up visits, ADR data are collected. In order to assess the appropriateness of therapy, while monitoring regional pharmaceutical expenditure, linkage from administrative flows and TPs data (issued from regional biological drugs registries) has been performed. RESULTS: Combining administrative data with longitudinal clinical data from registries, it’s possible to identify the treated patients profile (comorbidities), to perform sub-populations analysis and to evaluate long-term effects in a real-life setting. Each user (Clinician, Pharmacist, Regional Administrator), according to their profile rights, can access an online dashboard tool for analyzing data and monitoring their prescriptions / dispensations KPIs. Three types of drug distribution not covered by TP have emerged: drug dispensation to a patient not inserted in the disease registry, delivery of an active ingredient other than the one required in the TP, distribution of the drug out of the period of validity of the TP. CONCLUSIONS: Cineca Innovative Drug Registry platform allows data access for all user-profiles and provides all stakeholders with tools for monitoring and assessing therapeutic appropriateness. Furthermore, the integration between multiple data sources (administrative flows and clinical DB) represents a Health Value Added for all stakeholders. Through the merged DB, new KPIs are automatically generated and can be examined and monitored for guaranteeing cost sustainability and defining therapeutic paths in a real-world setting.